Biofrontera reports further positive results from the phase III trial with Ameluz® for photodynamic therapy of actinic keratoses on the extremities and trunk/neck
16 avr. 2019 07h30 HE
|
Biofrontera AG
Leverkusen, Germany, April 16, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports...
Biofrontera, Inc., USA, acquires Cutanea Life Sciences, Inc., USA
25 mars 2019 10h00 HE
|
Biofrontera AG
Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 25, 2019 (GLOBE NEWSWIRE) -- Biofrontera Inc., USA (“Biofrontera”), a wholly owned subsidiary of Biofrontera AG (NASDAQ ticker...
Biofrontera Reports Positive Phase III Results with Ameluz® for photodynamic therapy of actinic keratoses on the extremities and trunk/neck
20 mars 2019 10h50 HE
|
Biofrontera AG
Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 20, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical...
Photodynamic Therapy Fundamentals Presented
22 mars 2013 14h06 HE
|
American Society for Laser Medicine & Surgery, Inc. (ASLMS)
WAUSAU, Wis., March 22, 2013 (GLOBE NEWSWIRE) -- Laser 2013 will offer a session on Photodynamic Therapy, Friday, April 5, as part of the 33rd Annual Conference of the American Society for Laser...